Login to Your Account

Armetheon Seeks to Repurpose Stalled Late-Stage Compounds

By Marie Powers
Staff Writer

Friday, April 12, 2013
Privately held Armetheon Inc. was launched in October 2011 with a mission to create novel antibiotics for drug-resistant bacteria. However, that program quickly took a back seat when the founders discovered a new use for a compound, tecarfarin, advanced by another biotech where several of them had played leading roles.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription